A systematic literature review was performed to summarize effectiveness outcomes reported from real-world evidence (RWE) studies in people with HIV (PWH) with baseline characteristics that were not consistent with inclusion criteria for the doravirine and lamivudine (DTG + 3TC) phase 3 clinical development program randomized controlled trials (RCTs) either initiated or switched to DTG + 3TC.

Methods
- Conducted a systematic literature review according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement.
- RWE studies were included.
- Studies were included if PWH with baseline characteristics not consistent with clinical development program RCT inclusion criteria.

Results
- This review includes 122 publications from 103 RWE studies of 44 unique cohorts.
- Over ~1500 patient-years (PYFU).
- No studies reported effectiveness outcomes in PWH with baseline characteristics not consistent with clinical development program RCT inclusion criteria.
- Outcomes from these RWE subgroups reinforce the clinical effectiveness of DTG + 3TC and further inform its use in routine clinical practice.

Conclusions
- In real-world cohorts reflective of routine clinical practice, DTG + 3TC was reported with PWH with broad baseline characteristics.
- Outcomes from these RWE subgroups reinforce the clinical effectiveness of DTG + 3TC and further inform its use in routine clinical practice.